The recent surge in funding into niche pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Investor Pharma." https://kobipqyx580017.bloggazzo.com/38953444/elite-roller-pharma-the-hazardous-bet